A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure

International Journal of Clinical Practice

Volumn 54, Issue 1, 2000, Pages

  Tonkon, M ^e   Awan, N ^a   Niazi, I ^b   Hanley, P ^e   Baruch, L ^c   Wolf, R A ^d   Block, Alan J ^d  

^a Center for Heart Failure Research   (United States)

^b Arrhythmia Center   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; IRBESARTAN; LISINOPRIL; QUINAPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EXERCISE TOLERANCE; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TIME; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT SELECTION; PILOT PROJECTS; PLACEBOS; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0343484917     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. ACC/AHA Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 1995; 26: 1376-1398.
2. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18: 736-753.
3. The National Heart Foundation of New Zealand Cardiac Society of Australia and New Zealand and the Royal New Zealand College of General Practitioners Working Party. New Zealand guidelines for the management of chronic heart failure. NZ Med J 1997; 110: 99-107.
4. Narang R, Swedberg K, Cleland JG. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur Heart J 1996; 17: 120-134.
5. Garg R, Yusuf S. Overview of randomized trials of ACE inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-1456.
6. van den Meiracker AH, Man in't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect antihypertensive response? J Hypertens 1992; 10: 803-812.
7. Cleland JGF, Morgan K. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. Curr Opin Cardiol 1996; 11: 252-262.
8. Wolny A, Clozel JP, Rein J et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80: 219-227.
9. Eberhardt RT, Kevak RM, Kang PM et al. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993; 33: 1023-1038.
10. Gottlieb SS, Dickstein K, Fleck E et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88(pt 1): 1602-1609.
11. Crozier I, Ikram H, Awan N et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-697.
12. LeJemtel T, Awan N, Liang C et al. Irbesartan - a new angiotensin II antagonist: acute hemodynamic effect in patients with heart failure. Circulation 1996; 94(suppl): 3643-3644.
13. Havranek EP, Thomas I, Smith WB et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33: 1174-1181.
14. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826-834.
15. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994; 251: 143-150.
16. Ribstein J, Sissmann J, Picard A et al. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects (Abstract). J Hypertens 1994; 12: 131.
17. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992; 42: 1020-1029.
18. Baruch L, Anand IS, Judd DL et al. Hemodynamic response to AT1 receptor blockade with valsartan in ACE inhibitor-treated patients with heart failure (Abstract). Circulation 1996; 94(suppl 1): 1-428.
19. Hamroff G. Blaufarb I, Mancini D et al. Angiotensin II receptor blockade further reduces afterload safely in patients maximally treated with ACE inhibitors for heart failure. (Abstract) Circulation 1996; 94(suppl 1): 1-428.
20. Spinale FG, de Gasparo M, Whitebread S et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997; 96: 2385-2396.
21. Kromer EP, Riegger GAJ, Liebau G et al. Effectiveness of converting enzyme inhibition (enalapril) for mild congestive heart failure. Am J Cardiol 1986; 57: 459-462.
22. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9: 188-197.
23. Chang Pl, Pitt B. Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure. Cardiologia 1994; 39(suppl 1): 409-411.
24. Pool JL, Guthrie RM, Littlejohn TW III et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-470.
25. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995; 25: 22-29.
26. Reeves RA, Lin C-S, Kassler-Taub K et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31: 1311-1316.
27. Ribstein J, Picard A, Armagnac C et al. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects. (Abstract) J Hypertens 1997; 15(suppl 4): S117.
28. Klinger G, Jaramillo N, Ikram H et al. Effects of losartan on exercise capacity, morbidity and mortality in patients with symptomatic heart failure. J Am Coll Cardiol 1997; 29: 205A.
29. Dickstein K, Chang P, Willenheimer R et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-445.
30. Lang RM, Elkayam U, Yellen LG et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol 1997; 30: 983-991.
31. Vijay N, Alhaddad IA, Denny DM et al. Irbesartan compared with lisinopril in patients with mild to moderate heart failure. (Abstract) J Am Coll Cardiol 1998; 31(suppl A): 188A.
32. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
33. Azizi M, Chatellier G, Guyene T-T et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825-834.